ArticleJCI insight2021
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Open access · goldAbstract readComparative Study
In one paragraph
Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Timing, Titre, and Host Determinants of Convalescent Plasma Efficacy in COVID-19: A Systematic Review With Design-Stratified Narrative Synthesis.Reviews in medical virology · 2026Pooled it
- Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Pooled it
- Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression.British journal of anaesthesia · 2021Pooled it
- CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence.European journal of clinical investigation · 2021Pooled it
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.Mayo Clinic proceedings · 2021Pooled it
- Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.Cell reports. Medicine · 2022Trial
- Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Article
- SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients.PloS one · 2023Article
- Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022Article
- Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.Transfusion · 2022Article
- Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).Journal of intensive medicine · 2022Article
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.Clinical microbiology reviews · 2022Review
- Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.Molecular biomedicine · 2022Review
- Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection.Infectious diseases and therapy · 2022Article
- Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes.PLoS computational biology · 2022Article
- Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.PloS one · 2022Article
- Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response.Nature communications · 2021Article
- Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.The Journal of clinical investigation · 2021Article
- COVID-19 convalescent plasma therapy: hit fast, hit hard!Vox sanguinis · 2021Article
Corrections and comments
- Update of
Authors and funding
55 authors at 4 institutions in 3 countries.
Hyun Ah YoonDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Rachel BartashDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Inessa GendlinaDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Johanna RiveraDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Antonio NakouziDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Robert H BortzDepartment of Microbiology and Immunology and.
Ariel S WirchnianskiDepartment of Microbiology and Immunology and.
Monika ParoderDepartment of Pathology and.
Karen FehnDepartment of Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Leana Serrano-RahmanDepartment of Pathology and.
Rachelle BabbDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Uzma N SarwarDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Denise HaslwanterDepartment of Microbiology and Immunology and.
Ethan LaudermilchDepartment of Microbiology and Immunology and.
Catalina FlorezDepartment of Microbiology and Immunology and.
M Eugenia DieterleDepartment of Microbiology and Immunology and.
Rohit K JangraDepartment of Microbiology and Immunology and.
J Maximilian FelsDepartment of Microbiology and Immunology and.
Karen TongDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Margarette C MarianoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Olivia VergnolleDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
George I GeorgievDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Natalia G HerreraDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Ryan J MalonisDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Jose A QuirozDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Nicholas C MoranoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Gregory J KrauseDepartment of Developmental & Molecular Biology.
Joseph M SweeneyDepartment of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA.
Kelsie CowmanDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Stephanie AllenAlbert Einstein College of Medicine, Bronx, New York, USA.
Jayabhargav AnnamAlbert Einstein College of Medicine, Bronx, New York, USA.
Ariella ApplebaumAlbert Einstein College of Medicine, Bronx, New York, USA.
Daniel BarbotoAlbert Einstein College of Medicine, Bronx, New York, USA.
Ahmed KhokharAlbert Einstein College of Medicine, Bronx, New York, USA.
Brianna J LallyAlbert Einstein College of Medicine, Bronx, New York, USA.
Audrey LeeAlbert Einstein College of Medicine, Bronx, New York, USA.
Max LeeAlbert Einstein College of Medicine, Bronx, New York, USA.
Avinash MalaviyaAlbert Einstein College of Medicine, Bronx, New York, USA.
Reise SampleAlbert Einstein College of Medicine, Bronx, New York, USA.
Xiuyi A YangAlbert Einstein College of Medicine, Bronx, New York, USA.
Yang LiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Rafael RuizNetwork Performance Group, Montefiore Medical Center, Bronx, New York, USA.
Raja ThotaNetwork Performance Group, Montefiore Medical Center, Bronx, New York, USA.
Jason BarnhillDepartment of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA.
Doctor Y GoldsteinDepartment of Pathology and.
Joan UehlingerDepartment of Pathology and.
Scott J GarforthDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Steven C AlmoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Jonathan R LaiDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Morayma Reyes GilDepartment of Pathology and.
Amy S FoxDepartment of Pathology and.
Kartik ChandranDepartment of Microbiology and Immunology and.
Tao WangDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Johanna P DailyDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Liise-Anne PirofskiDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Albert Einstein College of Medicine · USUnited States Military Academy · USInstitut thématique Génétique, génomique et bioinformatique · FRMontefiore Medical Center · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MMayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vinayaka R. Prasad · 2017 to 2026
$28.3MCTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7MPrometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral ThreatsU19AI142777 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHANDRAN, KARTIK · 2019 to 2023
$21.9MCore-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3MTRAINING PROGRAM IN CELLULAR &MOLEC. BIOLOGY &GENETICST32GM007491 · NIGMS · YESHIVA UNIVERSITY · PI QUERY, CHARLES C · 1985 to 2021
$17.0MNovel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV RemissionR01AI145024 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ALMO, STEVEN C., GOLDSTEIN, HARRIS · 2019 to 2023
$4.1MAntibodies, B cells and resistance to human cryptococcosisR01AI143453 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PIROFSKI, LIISE-ANNE · 2019 to 2024
$3.2MEngineered, multispecific antibodies as broad anti-filovirus therapeuticsR01AI125462 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI LAI, JONATHAN R. · 2017 to 2020
$3.0MPlasmodium phospholipase A2s as potential novel drug targetsR21AI141367 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DAILY, JOHANNA PATRICIA · 2019 to 2020
$459kNCATS NIH HHS UL1 TR001073NCATS NIH HHS UL1 TR002377NCATS NIH HHS UL1 TR002556NCI NIH HHS P30 CA013330NIAID NIH HHS F30 AI150055NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI125462NIAID NIH HHS R01 AI143453NIAID NIH HHS R01 AI145024NIAID NIH HHS R21 AI141367NIAID NIH HHS U19 AI142777NIGMS NIH HHS T32 GM007288NIGMS NIH HHS T32 GM007491
Abstract
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.
Indexed as
AdultAgedAged, 80 and overAge FactorsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 SerotherapyFemaleHospital MortalityHumansImmunization, PassiveMaleMiddle AgedNew York CityPropensity ScoreAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusCOVID-19ImmunoglobulinsInfectious disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.